ACAD Acadia Pharmaceuticals Inc
Price (delayed)
$17.56
Market cap
$2.93B
P/E Ratio
12.82
Dividend/share
N/A
EPS
$1.37
Enterprise value
$2.64B
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who
Highlights
The net income has surged by 76% since the previous quarter
The EPS has soared by 76% QoQ
The debt has decreased by 12% YoY but it has increased by 4% QoQ
The gross margin has declined by 3% year-on-year
Key stats
What are the main financial stats of ACAD
Market
Valuations
Earnings
Shares outstanding
166.79M
Market cap
$2.93B
Enterprise value
$2.64B
Price to earnings (P/E)
12.82
Price to book (P/B)
3.99
Price to sales (P/S)
3.04
EV/EBIT
10.24
EV/EBITDA
9.65
EV/Sales
2.76
Revenue
$957.8M
Gross profit
$875.96M
Operating income
$230.79M
Net income
$226.45M
EBIT
$258.08M
EBITDA
$273.96M
Free cash flow
$157.2M
Per share
Balance sheet
Liquidity
EPS
$1.37
EPS diluted
$1.36
Free cash flow per share
$0.95
Book value per share
$4.4
Revenue per share
$5.78
TBVPS
$6.44
Total assets
$1.19B
Total liabilities
$454.96M
Debt
$42.04M
Equity
$732.79M
Working capital
$543.45M
Debt to equity
0.06
Current ratio
2.38
Quick ratio
2.2
Net debt/EBITDA
-1.05
Margins
Efficiency
Dividend
EBITDA margin
28.6%
Gross margin
91.5%
Net margin
23.6%
Operating margin
24.1%
Return on assets
23%
Return on equity
39.5%
Return on invested capital
75%
Return on capital employed
32.5%
Return on sales
26.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACAD stock price
How has the Acadia Pharmaceuticals stock price performed over time
Intraday
-0.28%
1 week
-10.41%
1 month
-5.34%
1 year
-25.34%
YTD
-4.31%
QTD
-4.31%
Financial performance
How have Acadia Pharmaceuticals's revenue and profit performed over time
Revenue
$957.8M
Gross profit
$875.96M
Operating income
$230.79M
Net income
$226.45M
Gross margin
91.5%
Net margin
23.6%
The operating income has soared by 106% from the previous quarter
The operating margin has soared by 99% QoQ
The net income has surged by 76% since the previous quarter
The net margin has soared by 71% QoQ
Growth
What is Acadia Pharmaceuticals's growth rate over time
Valuation
What is Acadia Pharmaceuticals stock price valuation
P/E
12.82
P/B
3.99
P/S
3.04
EV/EBIT
10.24
EV/EBITDA
9.65
EV/Sales
2.76
The EPS has soared by 76% QoQ
The company's equity has surged by 70% YoY and by 27% QoQ
ACAD's price to book (P/B) is 49% lower than its 5-year quarterly average of 7.9 and 22% lower than its last 4 quarters average of 5.1
ACAD's P/S is 63% below its 5-year quarterly average of 8.2 and 5% below its last 4 quarters average of 3.2
ACAD's revenue is up by 32% YoY and by 3.1% QoQ
Efficiency
How efficient is Acadia Pharmaceuticals business performance
The ROS has soared by 83% QoQ
ACAD's return on invested capital has surged by 74% since the previous quarter
Acadia Pharmaceuticals's return on assets has surged by 56% QoQ
The ROE has soared by 53% from the previous quarter
Dividends
What is ACAD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACAD.
Financial health
How did Acadia Pharmaceuticals financials performed over time
The total assets is 161% more than the total liabilities
The total assets has soared by 59% YoY and by 22% from the previous quarter
The total liabilities has increased by 43% YoY and by 14% QoQ
The debt is 94% lower than the equity
The company's equity has surged by 70% YoY and by 27% QoQ
The debt to equity has declined by 45% year-on-year and by 14% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.